Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for EyePoint Pharmaceuticals

    Client Virtual Booth

    EYEPOINT PHARMACEUTICALS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    EyePoint Pharmaceuticals
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    480 Pleasant Street Suite B300 Watertown MA 02472 United States
    Telephone
    Telephone
    1-833-393-7646
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://eyepointpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/eyepointpharmaceuticals/
    Twitter
    Twitter
    https://twitter.com/EyePointPharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    https://www.globenewswire.com/news-release/2024/04/16/2863443/0/en/EyePoint-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    16 Apr 2024
    Share Share
    EyePoint Expands Scientific Advisory Board with WorldRenowned Retina Specialists
    EyePoint Expands Scientific Advisory Board with WorldRenowned Retina Specialists

    https://www.globenewswire.com/news-release/2024/04/02/2855773/0/en/EyePoint-Pharmaceuticals-Expands-Scientific-Advisory-Board-with-World-Renowned-Retina-Specialists.html

    GLOBENEWSWIRE
    02 Apr 2024
    Share Share
    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    https://www.globenewswire.com/news-release/2024/03/18/2847663/0/en/EyePoint-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    18 Mar 2024
    Share Share
    EyePoint Analysts Just Slashed This Year's Revenue Estimates By 22%
    EyePoint Analysts Just Slashed This Year's Revenue Estimates By 22%

    https://finance.yahoo.com/news/eyepoint-pharmaceuticals-inc-nasdaq-eypt-133226809.html

    YAHOO FINANCE
    09 Mar 2024
    Share Share
    EyePoint Pharma Reports Fourth Quarter and Full-Year 2023 Financial Results
    EyePoint Pharma Reports Fourth Quarter and Full-Year 2023 Financial Results

    https://www.globenewswire.com//news-release/2024/03/07/2842099/0/en/EyePoint-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Highlights-Recent-Corporate-Developments.html

    GLOBENEWSWIRE
    07 Mar 2024
    Share Share
    EyePoint Announces Appointment of Ramiro Ribeiro as Chief Medical Officer
    EyePoint Announces Appointment of Ramiro Ribeiro as Chief Medical Officer

    https://www.globenewswire.com//news-release/2024/03/04/2839395/0/en/EyePoint-Pharmaceuticals-Announces-Appointment-of-Ramiro-Ribeiro-M-D-Ph-D-as-Chief-Medical-Officer.html

    GLOBENEWSWIRE
    04 Mar 2024
    Share Share
    EyePoint to Report Fourth Quarter and Full-Year 2023 Financial Results
    EyePoint to Report Fourth Quarter and Full-Year 2023 Financial Results

    https://www.globenewswire.com//news-release/2024/02/29/2837829/0/en/EyePoint-Pharmaceuticals-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-7-2024.html

    GLOBENEWSWIRE
    29 Feb 2024
    Share Share
    EyePoint Pharma Announces Participation at Upcoming Investor Conferences
    EyePoint Pharma Announces Participation at Upcoming Investor Conferences

    https://www.globenewswire.com//news-release/2024/02/27/2835856/0/en/EyePoint-Pharmaceuticals-Announces-Participation-at-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    27 Feb 2024
    Share Share
    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    https://www.globenewswire.com//news-release/2024/02/16/2830681/0/en/EyePoint-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    16 Feb 2024
    Share Share
    EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
    EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

    https://www.globenewswire.com/news-release/2024/02/03/2823161/0/en/EyePoint-Pharmaceuticals-Announces-Two-Presentations-of-Topline-Data-with-Additional-Subgroup-Analyses-from-the-Phase-2-DAVIO-2-Clinical-Trial-of-EYP-1901-for-the-Treatment-of-Wet-.html

    GLOBENEWSWIRE
    03 Feb 2024
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search